GALFLU:老年人高剂量与标准剂量流感疫苗个体随机实用试验的方法与操作框架
GALFLU是一项在西班牙Galicia地区65-79岁人群中开展的实用、个体随机、开放标签临床试验,比较高剂量与标准剂量灭活流感疫苗在2023-2024和2024-2025流感季的真实世界效果。试验将个体随机嵌入区域疫苗接种项目并利用数字健康登记系统收集数据,主要结局为针对流感或肺炎相关住院复合终点的相对疫苗效力。该研究展示了在常规临床实践中开展大规模实用随机对照试验的可行性。
要点
- GALFLU将个体随机嵌入区域疫苗接种项目,验证了大规模实用随机对照试验在常规实践中的可行性。
- 主要结局为针对流感或肺炎相关住院复合终点的相对疫苗效力。
- 试验利用数字健康登记系统实现低负担、全面的真实世界数据收集。
核心结论
- GALFLU展示了在常规公共卫生环境中嵌入大规模实用随机对照试验的可行性,为未来类似评估提供了可复制的蓝图。
研究设计与样本
- 实用、个体随机、开放标签临床试验,在西班牙Galicia地区65-79岁成人中比较高剂量与标准剂量灭活流感疫苗,覆盖2023-2024和2024-2025两个流感季。
- 试验将个体随机嵌入区域疫苗接种项目,并利用数字健康登记系统在真实世界条件下进行全面、低负担的数据收集。
- GALFLU方案获Galicia药物研究伦理委员会批准(CEIm-G,代码2023/374),参与完全自愿。
- 试验注册于EU Clinical Trials Register(2023-506,977-36-00)和ClinicalTrials.gov(NCT06141655)。
主要发现
- GALFLU证明了在常规临床实践中开展大规模实用随机对照试验的可行性。
- GALFLU的研究结果将在同行评议科学期刊和科学会议上传播,并与相关主管部门共享。
关键数值与推荐
- 主要结局为针对流感或肺炎相关住院复合终点的相对疫苗效力(rVE)。
- 次要和探索性结局包括针对心肺住院、实验室确诊流感住院、全因住院、死亡和医疗服务利用的rVE。
临床怎么用
- GALFLU为在常规公共卫生环境中嵌入实用评估提供了可复制的操作框架,可供其他地区或项目借鉴。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimizing influenza vaccination in older adults is a public health priority. While high-dose inactivated influenza vaccines (HD-IIV) have shown superior immunogenicity and efficacy over standard-dose vaccines (SD-IIV), there is a shortage of large-scale, individually randomized data evaluating real-world effectiveness against severe outcomes-especially within publicly funded health systems. METHODS: GALFLU is a pragmatic, individually randomized, open-label clinical trial comparing HD-IIV and SD-IIV in adults aged 65-79 years in Galicia, Spain, during the 2023-2024 and 2024-2025 influenza seasons. The trial embedded individual randomization into the regional vaccination program and exploited digital health registries for comprehensive, low-burden data collection under real-world conditions. The primary outcome is relative vaccine effectiveness (rVE) against a composite of influenza- or pneumonia-related hospitalizations. Secondary and exploratory outcomes include rVE against cardio-respiratory hospitalization, laboratory-confirmed influenza hospitalization, all-cause hospitalization, mortality, and healthcare utilization. The GALFLU protocol was approved by the Comité de ética de la investigación con medicamentos de Galicia (CEIm-G, code 2023/374). Participation was fully voluntary. RESULTS: GALFLU demonstrated the feasibility of large-scale, pragmatic randomized controlled trials within routine clinical practice. Findings from GALFLU will be disseminated in peer-reviewed scientific journals and scientific meetings and shared with relevant authorities. CONCLUSIONS: GALFLU provides a reproducible blueprint for future pragmatic evaluations embedded in routine public health settings. TRIAL REGISTRATION: The trial was registered in EU Clinical Trials Register (2023-506,977-36-00); ClinicalTrials.gov (NCT06141655).
引用
- Mallah N, Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, et al. Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults. Vaccine. 2026. PMID: 41806760. doi:10.1016/j.vaccine.2026.128435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。